EPO and anemia (phenotype): SVR was significantly higher in group 3 patients (49%) due to a relevant decline in relapse rate.It has been suggested that the use of erythropoietin may be an appropriate strategy for managing anemia, improving quality of life, and increasing adherence to therapy, particularly in patients with genotype 1 infection [29].